TY - JOUR
T1 - EFFECT OF NON-STEROIDAL ANTI-INFLAMMATORY DRUGS ON CONTROL OF HYPERTENSION BY BETA-BLOCKERS AND DIURETICS
AU - Wong, D. G.
AU - Lamki, L.
AU - Spence, J. D.
AU - Freeman, D.
AU - Mcdonald, J. W.D.
N1 - Funding Information:
This work perfusion. was supported by grants from the Australian Heart Foundation (to S. L. S.), from the National Health and Medical Research Council of Australia (to J. D. H.), and from the William Buckland Foundation and the Victor Hurley Medical Research Fund (to J. A. W.). Correspondence should be addressed to S. L. S.
Funding Information:
coordination of the data collection. D. G. W. was a recipient of a research fellowship funded by Merck Frosst Canada Ltd and awarded by the Canadian Society for Clinical Pharmacology.
PY - 1986/5/3
Y1 - 1986/5/3
N2 - The effect of sulindac on renal function and blood pressure was compared with those of placebo, piroxicam, and naproxen in 20 patients with primary hypertension being treated with a diuretic and a beta-blocker. Although the three non-steroidal anti-inflammatory drugs (NSAIDs) did not differ in their effect on renal function (weight, glomerular filtration rate, creatinine clearance) or on serum thromboxane and plasma 6-keto prostaglandin F1α (6-keto PGF1α), blood pressure was significantly lower with sulindac than with placebo, piroxicam, or naproxen. These differences were associated with less renal cyclooxygenase inhibition by sulindac (reflected by urinary thromboxane B2 and 6-keto PGF1α) than by other NSAIDs. The findings suggest that the blood pressure differences reflect vasodilation due to differences in the balance between systemic and renal effects of the NSAIDs.
AB - The effect of sulindac on renal function and blood pressure was compared with those of placebo, piroxicam, and naproxen in 20 patients with primary hypertension being treated with a diuretic and a beta-blocker. Although the three non-steroidal anti-inflammatory drugs (NSAIDs) did not differ in their effect on renal function (weight, glomerular filtration rate, creatinine clearance) or on serum thromboxane and plasma 6-keto prostaglandin F1α (6-keto PGF1α), blood pressure was significantly lower with sulindac than with placebo, piroxicam, or naproxen. These differences were associated with less renal cyclooxygenase inhibition by sulindac (reflected by urinary thromboxane B2 and 6-keto PGF1α) than by other NSAIDs. The findings suggest that the blood pressure differences reflect vasodilation due to differences in the balance between systemic and renal effects of the NSAIDs.
UR - http://www.scopus.com/inward/record.url?scp=0022615449&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0022615449&partnerID=8YFLogxK
U2 - 10.1016/S0140-6736(86)91271-7
DO - 10.1016/S0140-6736(86)91271-7
M3 - Article
C2 - 2871333
AN - SCOPUS:0022615449
SN - 0140-6736
VL - 327
SP - 997
EP - 1001
JO - The Lancet
JF - The Lancet
IS - 8488
ER -